The hr-HPV based cervical cancer screening: results of a four-years experience in a single screening center of Italy

Purpose of Investigation: The study was performed to evaluate four years of experience (2012-2015) in high risk-human papillo-mavirus (hr-HPV) testing in the cervical cancer screening in Latina (Italy). Materials and Methods: The hr-HPV as primary test is per-formed only on women aged 35-64, followed by a Pap test as triage, while women aged 25-34 are invited to perform only a Pap test. Results: Women resulted positive to hr-HPV test and positive to Pap test were 5.6% and 4.1%, respectively. Among women aged 25-34, the hr-HPV test was used as triage for women with atypical squamous cells of undetermined significance (ASCUS) and 69.9% resulted positive to the test. The positive predictive value (PPV) for high cervical intraepithelial lesions (HSIL) was higher in women aged 35-64 (9.9% vs. 6.9%), while the detection rate (DR) for HSIL was higher in young women (2.4‰ vs. 1.2‰). The authors found that 52.5%of women with hr-HPV+/Pap test resulted with hr-HPV+ at one-year recall and the DR for HSIL lesions of this population was very low (0.27‰). Discussion: The present data confirms that the application of hr-HPV test showed elevated performance in cervical cancer screening and that the application of hr-HPV test in managing ASCUS leads to a decreased use of inappropriate colposcopies. Finally, it may be useful to extend the period of follow-up for women hr-HPV+/Pap test to reduce unnecessary colposcopies.

Human papillomavirus; Cervical cancer; Screening; hr-HPV test; Pap test.

[1] Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M.: “Human papillomavirus genotype specificity of hyibrid capture 2”. J. Clin. Microbiol., 2008, 46, 2595.

[2] Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al.: “Guidelines for Human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older”. Int. J. Cancer, 2009, 124, 516.

[3] Italian group for cervical screening (GISCi): “Recommendations on the hr-HPV test as primary screening test and review of the role of the pap test”. Available at: www.gisci.it/documenti/docu-menti_ gisci/ documento_hpv.pdf [In Italian]

[4] Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al.: “Management of women who test positive for high-risk types of human papillomavirus: the HART study”. Lancet, 2003, 362, 1871.

[5] Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al.: “Results at recruitment from a random-ized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test”. J. Natl. Cancer Inst., 2008, 100, 492.

[6] Gillio-Tos A., De Marco L., Carozzi F.M., Del Mistro A., Girlando S., Burroni E., et al.: “Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Tech-nologies for Cervical Cancer (NTCC) study”. J. Clin. Microbiol., 2013, 51, 2901.

[7] Anttila A., Arbyn M., De Vuyst H., Dillner J., Dillner L., Franceschi S., et al.: “European guidelines for quality assurance in cervical cancer screening”. Second Edition – Supplements. Luxembourg: Publications Office of the European Union, 2015.

[8] National Plan of Prevention 2010-2012: “Priority central action concerning the “Definition of technical documents for the synthe-sis of scientific evidence” to support the planning, monitoring and evaluation of cancer prevention in population at risk population”. Ministry of Health DGPRE 001068-P-14/01/2013. Available at:www.osservatorionazionalescreening.it/sites/default/files/alle-gati/ Screening.pdf

[9] Ronco G., Accetta G., Angeloni C., Arbyn M., Barzon L., Biggeri A., et al.: “Health Technology Assessment. “Research of Human Papillomavirus (HPV) DNA as a primary test for the screening of cervical cancer precursors. HPV DNA based primary screening for cervical cancer precursors”. Epidemiologia e Prevenzione, 2012, 36, S1.

[10] Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M., et al.: “The 2001 Bethesda System: terminology for re-porting results of cervical cytology”. JAMA, 2002, 287, 2114.

[11] Italian group for cervical screening (GISCi): “Indicators for mon-itoring of screening programs using HPV test as a primary test”. Available at: http://www.gisci.it/documenti/documenti_gisci/HPV-indicatori-GISCi-2016.pdf [In Italian]

[12] Di Stefano F., Giorgi Rossi P., Carozzi F., Ronco G., Cacciani L., Vecchi S., et al.: “The implementation of DNA-HPV as a primary test in Italian cervical cancer screening programs. Data from the results of the MIDDIR Project. Methods for Investments/Disin-vestments and Distribution of health technologies in Italian Re-gions”. Available at: http://www.gisci.it/altri-documenti [In Italian]

[13] Barca A., Baiocchi D., Della Guardia M., Maltempi A., Quadrino F., Urbinelli L., et al.: “The oncology screening programs of the Lazio. Report 2010-2011”. 2013. Lazio Sanità, Agenzia di Sanità Pubblica. Available at: www.asplazio.it [In Italian]

[14] Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al.: “Efficacy of human papillomavirus test-ing for the detection of invasive cervical cancers and cervical in-traepithelial neoplasia: a randomized controlled trial”. Lancet Oncol., 2010, 11, 249.

[15] Ko V., Nanji S., Tambouret R.H., Wilbur D.C.: “Testing for HPV as an objective measure for quality assurance in gynecologic cy-tology: positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio”. Cancer, 2007, 111, 67.

[16] Arbyn M., Roelens J., Simoens C., Buntinx F., Paraskevaidis E., Martin-Hirsch P.P., et al.: “Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions”. Cochrane Database Syst Rev., 2013, 3, CD008054.

[17] Giorgi Rossi P., Carozzi F., Collina G., Confortini M., Dalla Palma P., De Lillo M. et al.: “HPV testing is an efficient manage-ment choice for women with inadequate liquid-based cytology in cervical cancer screening”. Am. J. Clin. Pathol., 2012, 138, 65.

[18] Chiappetta C., Puggioni C., Lendaro E., Cacciotti J., Cirenza M., Zaralli R., et al.: “Management of women aged 25-34 with diag-nosis of ASCUS in the screening center of Latina”. Int. J. Clin. Exp. Pathol., 2016, 9, 8611.

[19] Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N. E., Lorey T., et al.: “Five-year risks of CIN3+ and cervical can-cer for women who test pap-negative but are HPV-positive”. J. Low. Genit. Tract Dis., 2013, 17, S56.

[20] Chiappetta C., Puggioni C., Lendaro E., Cacciotti J., Zaralli R., Migliore G., et al.: “Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall”. Int. J. Clin. Exp. Pathol., 2015, 8, 16089.